TriStrata/Mary Kay suit
This article was originally published in The Rose Sheet
Executive Summary
Wilmington, Del. federal court denied Mary Kay's post-trial motions to set aside jury verdict in alpha hydroxy acid patent infringement case, and entered final judgment, with interest, in TriStrata's favor, NeoStrata division reports April 5. Interest on back royalties will bring total amount of the judgment to about $41.4 mil., firm notes. Mary Kay had sought to set aside a 2005 jury verdict, which found the company infringed three TriStrata patents and required direct-seller to pay $26.4 mil. TriStrata won similar AHA patent infringement cases against Valeant Pharmaceuticals, which also failed to overturn a jury verdict (1"The Rose Sheet" March 10, 2004, In Brief)...
You may also be interested in...
Tristrata lawsuit
Valeant Pharmaceutical's motion seeking to overturn a jury verdict finding the company infringed two patents held by Tristrata Corporation and requesting a new trial is rejected by Wilmington, Del. federal court, according to parent company NeoStrata. Court also issues a permanent injunction prohibiting Valeant from the "manufacture, sale and marketing of products covered by the infringed patents." In November, the court ruled that Valeant willfully infringed the two patents, which cover the use of alpha hydroxy acids "to enhance the therapeutic effect of other substances" (1"The Rose Sheet" Dec. 1, 2003, In Brief). Patent infringement suits are still pending against other firms including Mary Kay cosmetics and BeautiControl...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.